ArticleHereditas2026
Pan-cancer analysis of PDZK1IP1 reveals its role in tumorigenesis and tumor immunity: focused validation in thyroid carcinoma.
Article in Hereditas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPDZK1IP1 is a membrane protein linked to inflammation and cancer, but its role in the tumor immune microenvironment is poorly understood. This study systematically investigated the oncogenic and immunological functions of PDZK1IP1 via a pan-cancer analysis, with experimental validation in thyroid carcinoma (THCA).
methodsWe conducted a comprehensive bioinformatic analysis of PDZK1IP1 using publicly available platforms (TIMER, GEPIA, c-BioPortal, TISIDB, SangerBox) to examine its expression, diagnostic potential, prognostic relevance, and correlation with key immune features, including immune checkpoint genes, tumor mutational burden, neoantigen load, tumor stemness, and immune cell infiltration. Findings were validated in a THCA cohort using RT-PCR and immunohistochemistry.
resultsPDZK1IP1 was overexpressed in multiple cancers, showed significant diagnostic potential, and was a context-dependent prognostic marker, correlating with poor relapse-free survival in THCA. Its expression was strongly associated with tumor mutational burden, neoantigen load, tumor stemness, and the infiltration of various immune cells (particularly neutrophils) across multiple cancers. These findings were corroborated in THCA, in which PDZK1IP1 expression correlated with the infiltration of five distinct immune cell types. Functional enrichment analysis confirmed an association with neutrophil activation pathways.
conclusionsOur study identified PDZK1IP1 with dual functions, acting as both an oncogene and a modulator of the tumor immune microenvironment. These findings highlight its potential as a prognostic biomarker and therapeutic target for immunotherapy, especially in THCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.